Neurotensin regulates cortical glutamate transmission by modulating N-methyl-D-aspartate receptor functional activity: An in vivo microdialysis study

Journal of Neuroscience Research

Volumn 89, Issue 10, 2011, Pages 1618-1626

  Ferraro, Luca ^a   Beggiato, Sarah ^a   Tomasini, Maria Cristina ^a   Fuxe, Kjell ^b   Tanganelli, Sergio ^a   Antonelli, Tiziana ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cortical glutamate transmission; NMDA receptor; SR48692, NTS 1

Indexed keywords

GLUTAMIC ACID; MECLINERTANT; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTENSIN; NEUROTENSIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN LEVEL; CONCENTRATION RESPONSE; EXTRACELLULAR FLUID; IN VIVO STUDY; MALE; MICRODIALYSIS; NEUROTRANSMISSION; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT;

ANIMALS; CEREBRAL CORTEX; EXTRACELLULAR FLUID; GLUTAMIC ACID; MALE; MICRODIALYSIS; NEUROTENSIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, NEUROTENSIN; SYNAPTIC TRANSMISSION; UP-REGULATION;

EID: 79961210513     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22686     Document Type: Article

References (71)

1. Abekawa T, Ito K, Koyama T. 2006. Role of the simultaneous enhancement of NMDA and dopamine D1 receptor-mediated neurotransmission in the effects of clozapine on phencyclidine-induced acute increases in glutamate levels in the rat medial prefrontal cortex. Naunyn Schmiedebergs Arch Pharmacol 374: 177-193.
2. 3H]N-propylnorapomorphine binding sites. Acta Physiol Scand 117: 299-301.
3. Allen GV, Cheung RT, Cechetto DF. 1995. Neurochemical changes following occlusion of the middle cerebral artery in rats. Neuroscience 68: 1037-1050.
4. Antonelli T, Tomasini M C, Finetti S, Giardino L, Calzà L, Fuxe K, Soubriè P, Tanganelli S, Ferraro L. 2002. Neurotensin enhances glutamate excitotoxicity in mesencephalic neurons. J Neurosci Res 70: 66-773.
5. Antonelli T, Ferraro L, Fuxe K, Finetti S, Fournier J, Tanganelli S, De Mattei M, Tomasini MC. 2004. Neurotensin enhances endogenous extracellular glutamate levels in primary cultures of rat cortical neurons: involvement of neurotensin receptor in NMDA induced excitotoxicity. Cereb Cortex 14: 466-473.
6. Antonelli T, Fuxe K, Tomasini MC, Mazzoni E, Agnati LF, Tanganelli S, Ferraro L. 2007. Neurotensin receptor mechanisms and its modulation of glutamate transmission in the brain: relevance for neurodegenerative diseases and their treatment. Prog Neurobiol 83: 92-109.
7. Bean AJ, Roth RH. 1992. Dopamine-neurotensin interactions in mesocortical neurons. Evidence from microdialysis studies. Ann N Y Acad Sci 668: 43-53.
8. Belmeguenai A, Desrues L, Leprince J, Vaudry H, Tonon MC, Louiset E. 2003. Neurotensin stimulates both calcium mobilization from inositol trisphosphate-sensitive intracellular stores and calcium influx through membrane channels in frog pituitary melanotrophs. Endocrinology 144: 5556-5567.
9. Binder EB, Kinkead B, Owens MJ, Nemeroff CB. 2001. Neurotensin and dopamine interactions. Pharmacol Rev 53: 453-486.
10. Boules M, Fredrickson P, Richelson E. 2006. Bioactive analogs of neurotensin: focus on CNS effects. Peptides 27: 2523-2533.
11. Cáceda R, Kinkead B, Nemeroff CB. 2006. Neurotensin: role in psychiatric and neurological diseases. Peptides 27: 2385-2404.
12. Cáceda R, Kinkead B, Nemeroff CB. 2007. Involvement of neuropeptide systems in schizophrenia: human studies. Int Rev Neurobiol 78: 327-376.
13. Carraway R, Leeman SE. 1973. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem 248: 6854-6861.
14. Chalon P, Vita N, Kaghad M, Guillemot M, Bonnin J, Delpech B, Le Fur G, Ferrara P, Caput D. 1996. Molecular cloning of a levocabastine-sensitive neurotensin binding site. FEBS Lett. 386: 91-94.
15. Chen L, Yung KK, Yung WH. 2006. Neurotensin selectively facilitates glutamatergic transmission in globus pallidus. Neuroscience 141: 1871-1878.
16. Del Arco A, Mora F. 2002. NMDA and AMPA/kainate glutamatergic agonists increase the extracellular concentrations of GABA in the prefrontal cortex of the freely moving rat: modulation by endogenous dopamine. Brain Res Bull 57: 623-630.
17. Deutch AY, Zahm DS. 1992. The current status of neurotensin-dopamine interactions: issues and speculations. Ann N Y Acad Sci 668: 232-252.
18. 2 receptors and their function in rat striatum: Counteraction by NTR1-like receptor antagonist. Neuroreport 13: 763-766.
19. During MJ, Bean AJ, Roth RH. 1992. Effects of CNS stimulants on the in vivo release of the colocalized transmitters, dopamine and neurotensin, from rat prefrontal cortex. Neurosci Lett 140: 129-133.
20. Faggin BM, Zubieta JK, Rezvani AH, Cubeddu LX. 1990. Neurotensin-induced dopamine release in vivo and in vitro from substantia nigra and nucleus caudate. J Pharmacol Exp Ther 252: 817-825.
21. Ferraro L, Tanganelli S, O'Connor WT, Bianchi C, Ungerstedt U, Fuxe K. 1995. Neurotensin increases endogenous glutamate release in the neostriatum of the awake rat. Synapse 20: 362-364.
22. Ferraro L, O'Connor WT, Antonelli T, Fuxe K, Tanganelli S. 1997. Differential effects of intrastriatal neurotensin(1-13) and neurotensin(8-13) on striatal dopamine and pallidal GABA release. A dual-probe microdialysis study in the awake rat. Eur J Neurosci 9: 1838-1846.
23. Ferraro L, Antonelli T, O'Connor WT, Fuxe K, Soubrie P, Tanganelli S. 1998. The striatal neurotensin receptor modulates striatal and pallidal glutamate and GABA release: functional evidence for a pallidal glutamate-GABA interaction via the pallidal-subthalamic nucleus loop. J Neurosci 18: 6977-6989.
24. Ferraro L, Tomasini MC, Siniscalchi A, Fuxe K, Tanganelli S, Antonelli T. 2000. Neurotensin increases endogenous glutamate release in rat cortical slices. Life Sci 66: 927-936.
25. Ferraro L, Tomasini MC, Fernandez M, Bebe BW, O'Connor WT, Fuxe K, Glennon JC, Tanganelli S, Antonelli T. 2001. Nigral neurotensin receptor regulation of nigral glutamate and nigroventral thalamic GABA transmission: a dual-probe microdialysis study in intact conscious rat brain. Neuroscience 102: 113-120.
26. Ferraro L, Tomasini MC, Mazza R, Fuxe K, Fournier J, Tanganelli S, Antonelli T. 2008. Neurotensin receptors as modulators of glutamatergic transmission. Brain Res Rev 58: 365-373.
27. Ferraro L, Tomasini MC, Beggiato S, Guerrini R, Salvadori S, Fuxe K, Calzà L, Tanganelli S, Antonelli T. 2009. Emerging evidence for neurotensin receptor 1 antagonists as novel pharmaceutics in neurodegenerative disorders. Mini Rev Med Chem 9: 1429-1438.
28. Fuxe K, O'Connor WT, Antonelli T, Osborne PG, Tanganelli S, Agnati LF, Ungerstedt U. 1992. Evidence for a substrate of neuronal plasticity based on pre- and postsynaptic neurotensin-dopamine receptor interactions in the neostriatum. Proc Natl Acad Sci U S A 89: 5591-5595.
29. Fuxe K, Marcellino D, Borroto-Escuela DO, Frankowska M, Ferraro L, Guidolin D, Ciruela F, Agnati LF. 2010. The changing world of G protein-coupled receptors: from monomers to dimers and receptor mosaics with allosteric receptor-receptor interactions. J Recept Signal Transduct Res 30: 272-283.
30. Ghanizadeh A. 2010. Targeting neurotensin as a potential novel approach for the treatment of autism. J Neuroinflamm 7: 58.
31. Gully D, Canton M, Boidegrain R, Jeanjean F, Molimard JC, Poncelet M, Gueudet C, Heaulme M, Leyris R, Brouard A, Pelaprat D, Labbe-Jullie C, Mazella J, Soubrie P, Maffrand JP, Rostene W, Kitbagi P, Le Fur G. 1993. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc Natl Acad Sci U S A 90: 65-69.
32. Hanson GR, Singh N, Merchant K, Johnson M, Gibb JW. 1995. The role of NMDA receptor systems in neuropeptide responses to stimulants of abuse. Drug Alcohol Depend 37: 107-110.
33. Héaulme M, Leyris R, Soubrié P, Le Fur G. 1998. Stimulation by neurotensin of (3H)5-hydroxytryptamine (5HT) release from rat frontal cortex slices. Neuropeptides 32: 465-471.
34. Hertel P, Mathé JM, Nomikos GG, Iurlo M, Mathé AA, Svensson TH. 1995. Effects of D-amphetamine and phencyclidine on behavior and extracellular concentrations of neurotensin and dopamine in the ventral striatum and the medial prefrontal cortex of the rat. Behav Brain Res 72: 103-114.
35. 1 receptors in dopamine neurons. Eur J Neurosci 24: 2789-2800.
36. Katsanos GS, Anogianaki A, Castellani ML, Ciampoli C, De Amicis D, Orso C, Pollice R, Vecchiet J, Tetè S, Salini V, Caraffa A, Patruno A, Shaik YB, Kempuraj D, Doyle R, Antinolfi PL, Cerulli G, Conti CM, Fulcheri M, Neri G, Sabatino G. 2008. Biology of neurotensin: revisited study. Int J Immunopathol Pharmacol 21: 255-259.
37. Kinkead B, Nemeroff CB. 2006. Novel treatments of schizophrenia: targeting the neurotensin system. CNS Neurol Disord Drug Targets 5: 205-218.
38. 1). Peptides 27: 2461-2468.
39. Kitabgi P, Carraway R, Leeman SE. 1976. Isolation of a tridecapeptide from bovine intestinal tissue and its partial characterization as neurotensin. J Biol Chem 251: 7053-7058.
40. Lan JY, Skeberdis VA, Jover T, Grooms SY, Lin Y, Araneda RC, Zheng X, Bennett MV, Zukin RS. 2001. Protein kinase C modulates NMDA receptor trafficking and gating. Nat Neurosci 4: 382-390.
41. 2+ signalling and synaptic plasticity. Biochem Soc Trans 37: 1369-1374.
42. 1 receptor. Cell 111: 219-230.
43. 2 receptors in rat neostriatal sections. Neuroreport 5: 1621-1624.
44. 2 receptor in rat nucleus accumbens: a receptor binding and microdialysis study. J Neural Transm Genet Sect 102: 125-137.
45. Li Z, Boules M, Williams K, Peris J, Richelson E. 2010. The novel neurotensin analog NT69L blocks phencyclidine (PCP)-induced increases in locomotor activity and PCP-induced increases in monoamine and amino acids levels in the medial prefrontal cortex. Brain Res 1311: 28-36.
46. López-Gil X, Babot Z, Amargós-Bosch M, Suñol C, Artigas F, Adell A. 2007. Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacology 32: 2087-2097.
47. Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, Varney MA. 2003. Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 117: 697-706.
48. 2+ in mammalian neurons. Trends Pharmacol Sci 11: 254-260.
49. 3 receptors. Peptides 27: 2469-2475.
50. Mazella J, Vincent JP. 2006b. Internalization and recycling properties of neurotensin receptors. Peptides 27: 2488-2492.
51. McMahon BM, Boules M, Warrington L, Richelson E. 2002. Neurotensin analogs indications for use as potential antipsychotic compounds. Life Sci 70: 1101-1119.
52. Moghaddam B, Adams B, Verma A, Daly D. 1997. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17: 2921-2927.
53. 2+-mediated nitrosative stress in neurodegenerative diseases: possible pharmacological strategies. Cell Calcium. 47: 190-197.
54. Nemeroff CB. 1980. Neurotensin: perchance an endogenous neuroleptic? Biol Psychiatry 15: 283-302.
55. Nemeroff CB, Cain ST. 1985. Neurotensin-dopamine interactions in the CNS. Trends Pharmacol Sci 6: 201-205.
56. Paxinos G, Watson C. 1986. The rat brain in stereotaxic coordinates. New York: Academic Press.
57. 1 receptor function by physical interaction with the NMDA receptors. J Neurosci 24: 1149-1158.
58. Petkova-Kirova P, Rakovska A, Della Corte L, Zaekova G, Radomirov R, Mayer A. 2008. Neurotensin modulation of acetylcholine, GABA, and aspartate release from rat prefrontal cortex studied in vivo with microdialysis. Brain Res Bull 77: 129-135.
59. Petrie KA, Schmidt D, Bubser M, Fadel J, Carraway RE, Deutch AY. 2005. Neurotensin activates GABAergic interneurons in the prefrontal cortex. J Neurosci 25: 1629-1636.
60. Quirion R, Chiueh CC, Everist HD, Pert A. 1985. Comparative localization of neurotensin receptors on nigrostriatal and mesolimbic dopaminergic terminals. Brain Res 327: 385-389.
61. Radke JM, Owens MJ, Nemeroff CB. 2001. The effects of glutamate receptor agonists on neurotensin release using in vivo microdialysis. Eur J Pharmacol 411: 129-134.
62. Rettenbacher M, Reubi JC. 2001. Localization and characterization of neuropeptide receptors in human colon. Naunyn Schmiedebergs Arch Pharmacol 364: 291-304.
63. Sanz B, Exposito I, Mora F. 1993. Effects of neurotensin on the release of glutamic acid in the prefrontal cortex and striatum of the rat. Neuroreport 4: 1194-1196.
64. Singh NA, Bush LG, Gibb JW, Hanson GR. 1992. Role of N-methyl-D-aspartate receptors in dopamine D1-, but not D2-, mediated changes in striatal and accumbens neurotensin systems. Brain Res. 571: 260-264.
65. St.-Gelais F, Legault M, Bourque MJ, Rompré PP, Trudeau LE. 2004. Role of calcium in neurotensin-evoked enhancement in firing in mesencephalic dopamine neurons. J Neurosci 24: 2566-2574.
66. St.-Gelais F, Jomphe C, Trudeau LE. 2006. The role of neurotensin in central nervous system pathophysiology: what is the evidence? J Psychiatry Neurosci 31: 229-245.
67. Tanganelli S, von Euler G, Fuxe K, Agnati LF, Ungerstedt U. 1989. Neurotensin counteracts apomorphine-induced inhibition of dopamine release as studied by microdialysis in rat neostriatum. Brain Res 502: 319-324.
68. Tanganelli S, O'Connor WT, Ferraro L, Bianchi C, Beani L, Ungerstedt U, Fuxe K. 1994. Facilitation of GABA release by neurotensin is associated with a reduction of dopamine release in rat nucleus accumbens. Neuroscience 60: 649-657.
69. Vincent JP, Mazella J, Kitabgi P. 1999. Neurotensin and neurotensin receptors. Trends Pharmacol Sci 20: 302-309.
70. 2 receptors in rat striatal membranes following treatment with toluene. Acta Physiol Scand 135: 442-448.
71. Zhao D, Pothoulakis C. 2006. Effects of NT on gastrointestinal motility and secretion, and role in intestinal inflammation. Peptides 27: 2434-2444.